Cargando…

FRI415 Patient Preference And Proof-of-concept For A Once-daily Follicle Stimulating Hormone (FSH) Biosimilar Delivered Via An Orally Ingestible Robotic Pill (RT-112)

Disclosure: A. Yamaguchi: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. K. Horlen: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. N. Patel: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. V. Tran: Employee; Self; Rani Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Alyson, Horlen, Kyle, Patel, Nidhi, Tran, Vinh, Vo, April T, Medida, Ramya Lekha, Myers, Joshua T, Fung, Leonard C, Kaminskaya, Kristina, Mohan, Deepa, Nguyen, Vy, Nguyen, Son, Syed, Baber, Dhalla, Arvinder K, Imran, Mir, Hashim, Mir A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554912/
http://dx.doi.org/10.1210/jendso/bvad114.1608
_version_ 1785116528172072960
author Yamaguchi, Alyson
Horlen, Kyle
Patel, Nidhi
Tran, Vinh
Vo, April T
Medida, Ramya Lekha
Myers, Joshua T
Fung, Leonard C
Kaminskaya, Kristina
Mohan, Deepa
Nguyen, Vy
Nguyen, Son
Syed, Baber
Dhalla, Arvinder K
Imran, Mir
Hashim, Mir A
author_facet Yamaguchi, Alyson
Horlen, Kyle
Patel, Nidhi
Tran, Vinh
Vo, April T
Medida, Ramya Lekha
Myers, Joshua T
Fung, Leonard C
Kaminskaya, Kristina
Mohan, Deepa
Nguyen, Vy
Nguyen, Son
Syed, Baber
Dhalla, Arvinder K
Imran, Mir
Hashim, Mir A
author_sort Yamaguchi, Alyson
collection PubMed
description Disclosure: A. Yamaguchi: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. K. Horlen: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. N. Patel: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. V. Tran: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. A.T. Vo: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. R. Medida: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. J.T. Myers: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. L.C. Fung: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. K. Kaminskaya: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. D. Mohan: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. V. Nguyen: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. S. Nguyen: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. B. Syed: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. A.K. Dhalla: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. M. Imran: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. M.A. Hashim: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. Background: Biotherapeutics offer effective treatments for reproductive disorders, but require painful parenteral (e.g., subcutaneous (SC)) injections, representing a burden for patients which interferes with comfort and quality of life. We have developed an orally ingestible robotic pill (RP) that can deliver biotherapeutic agents with bioavailability rivalling or surpassing that of parenteral injections. Here, we provide 1) clinical evidence of patient preference for the daily oral RP over parenteral injection therapy and 2) data from a study of awake canines demonstrating comparable serum exposures of FSH via the oral RP versus SC injection. Methods:Patient Preference Study: A total of 150 participants currently using parenteral injections were enrolled and given a mock-RP having the same physical characteristics of a RP but without a needle or drug inside. After swallowing the mock-RP, participants were asked to complete a questionnaire evaluating their experience and their preference for a pill vs. parenteral injection. Nonclinical Proof-of-Concept: Single doses of RT-112 (150 IU (n=7) and 450 IU (n=8)) were orally administered to awake, fasted Beagle dogs (7.0-13.0 kg body weight); a control group (n=3) received a dose of 20 IU/kg (∼180 IU) FSH via SC injection. Serial blood samples were collected over 5 days and serum FSH concentrations were quantified via a qualified ELISA. Results: All participants (150/150) in the patient preference study were able to swallow the mock-RP without any adverse events. Based on the questionnaire, the overall preference for an oral pill over parenteral injection was 91%, irrespective of age (21-50, 51-65, 66-75 years). Oral administration of FSH at the 2 doses via RT-112 to awake canines elicited dose proportional increases in serum drug concentrations. AUC(0-t) values for the 150 IU and 450 IU dose groups were 2101 ± 185 and 8179 ± 733 mIU*hr/mL, and C(max) values were 65 ± 13 and 224 ± 24 mIU/mL, respectively. The pharmacokinetic (PK) profile of the lower RT-112 dose was similar to that of the SC Control dose (AUC(0-t): 2131 ± 67 mIU*hr/mL, C(max): 52 ± 1 mIU/mL), with a relative bioavailability nearly identical (99%) to that of the SC injection. Conclusions: Patients strongly prefer an oral therapeutic option over parenteral therapy. In awake canines, FSH delivered via oral RP yielded bioavailability very similar to SC injection. These data provide early proof-of-concept of the feasibility of replacing the current parenteral injections of FSH with orally ingestible capsules utilizing the RP. Presentation: Friday, June 16, 2023
format Online
Article
Text
id pubmed-10554912
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105549122023-10-06 FRI415 Patient Preference And Proof-of-concept For A Once-daily Follicle Stimulating Hormone (FSH) Biosimilar Delivered Via An Orally Ingestible Robotic Pill (RT-112) Yamaguchi, Alyson Horlen, Kyle Patel, Nidhi Tran, Vinh Vo, April T Medida, Ramya Lekha Myers, Joshua T Fung, Leonard C Kaminskaya, Kristina Mohan, Deepa Nguyen, Vy Nguyen, Son Syed, Baber Dhalla, Arvinder K Imran, Mir Hashim, Mir A J Endocr Soc Reproductive Endocrinology Disclosure: A. Yamaguchi: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. K. Horlen: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. N. Patel: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. V. Tran: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. A.T. Vo: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. R. Medida: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. J.T. Myers: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. L.C. Fung: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. K. Kaminskaya: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. D. Mohan: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. V. Nguyen: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. S. Nguyen: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. B. Syed: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. A.K. Dhalla: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. M. Imran: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. M.A. Hashim: Employee; Self; Rani Therapeutics. Stock Owner; Self; Rani Therapeutics. Background: Biotherapeutics offer effective treatments for reproductive disorders, but require painful parenteral (e.g., subcutaneous (SC)) injections, representing a burden for patients which interferes with comfort and quality of life. We have developed an orally ingestible robotic pill (RP) that can deliver biotherapeutic agents with bioavailability rivalling or surpassing that of parenteral injections. Here, we provide 1) clinical evidence of patient preference for the daily oral RP over parenteral injection therapy and 2) data from a study of awake canines demonstrating comparable serum exposures of FSH via the oral RP versus SC injection. Methods:Patient Preference Study: A total of 150 participants currently using parenteral injections were enrolled and given a mock-RP having the same physical characteristics of a RP but without a needle or drug inside. After swallowing the mock-RP, participants were asked to complete a questionnaire evaluating their experience and their preference for a pill vs. parenteral injection. Nonclinical Proof-of-Concept: Single doses of RT-112 (150 IU (n=7) and 450 IU (n=8)) were orally administered to awake, fasted Beagle dogs (7.0-13.0 kg body weight); a control group (n=3) received a dose of 20 IU/kg (∼180 IU) FSH via SC injection. Serial blood samples were collected over 5 days and serum FSH concentrations were quantified via a qualified ELISA. Results: All participants (150/150) in the patient preference study were able to swallow the mock-RP without any adverse events. Based on the questionnaire, the overall preference for an oral pill over parenteral injection was 91%, irrespective of age (21-50, 51-65, 66-75 years). Oral administration of FSH at the 2 doses via RT-112 to awake canines elicited dose proportional increases in serum drug concentrations. AUC(0-t) values for the 150 IU and 450 IU dose groups were 2101 ± 185 and 8179 ± 733 mIU*hr/mL, and C(max) values were 65 ± 13 and 224 ± 24 mIU/mL, respectively. The pharmacokinetic (PK) profile of the lower RT-112 dose was similar to that of the SC Control dose (AUC(0-t): 2131 ± 67 mIU*hr/mL, C(max): 52 ± 1 mIU/mL), with a relative bioavailability nearly identical (99%) to that of the SC injection. Conclusions: Patients strongly prefer an oral therapeutic option over parenteral therapy. In awake canines, FSH delivered via oral RP yielded bioavailability very similar to SC injection. These data provide early proof-of-concept of the feasibility of replacing the current parenteral injections of FSH with orally ingestible capsules utilizing the RP. Presentation: Friday, June 16, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554912/ http://dx.doi.org/10.1210/jendso/bvad114.1608 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reproductive Endocrinology
Yamaguchi, Alyson
Horlen, Kyle
Patel, Nidhi
Tran, Vinh
Vo, April T
Medida, Ramya Lekha
Myers, Joshua T
Fung, Leonard C
Kaminskaya, Kristina
Mohan, Deepa
Nguyen, Vy
Nguyen, Son
Syed, Baber
Dhalla, Arvinder K
Imran, Mir
Hashim, Mir A
FRI415 Patient Preference And Proof-of-concept For A Once-daily Follicle Stimulating Hormone (FSH) Biosimilar Delivered Via An Orally Ingestible Robotic Pill (RT-112)
title FRI415 Patient Preference And Proof-of-concept For A Once-daily Follicle Stimulating Hormone (FSH) Biosimilar Delivered Via An Orally Ingestible Robotic Pill (RT-112)
title_full FRI415 Patient Preference And Proof-of-concept For A Once-daily Follicle Stimulating Hormone (FSH) Biosimilar Delivered Via An Orally Ingestible Robotic Pill (RT-112)
title_fullStr FRI415 Patient Preference And Proof-of-concept For A Once-daily Follicle Stimulating Hormone (FSH) Biosimilar Delivered Via An Orally Ingestible Robotic Pill (RT-112)
title_full_unstemmed FRI415 Patient Preference And Proof-of-concept For A Once-daily Follicle Stimulating Hormone (FSH) Biosimilar Delivered Via An Orally Ingestible Robotic Pill (RT-112)
title_short FRI415 Patient Preference And Proof-of-concept For A Once-daily Follicle Stimulating Hormone (FSH) Biosimilar Delivered Via An Orally Ingestible Robotic Pill (RT-112)
title_sort fri415 patient preference and proof-of-concept for a once-daily follicle stimulating hormone (fsh) biosimilar delivered via an orally ingestible robotic pill (rt-112)
topic Reproductive Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554912/
http://dx.doi.org/10.1210/jendso/bvad114.1608
work_keys_str_mv AT yamaguchialyson fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT horlenkyle fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT patelnidhi fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT tranvinh fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT voaprilt fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT medidaramyalekha fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT myersjoshuat fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT fungleonardc fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT kaminskayakristina fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT mohandeepa fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT nguyenvy fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT nguyenson fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT syedbaber fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT dhallaarvinderk fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT imranmir fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112
AT hashimmira fri415patientpreferenceandproofofconceptforaoncedailyfolliclestimulatinghormonefshbiosimilardeliveredviaanorallyingestibleroboticpillrt112